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Abstract
Objectives There is growing evidence that intracoronary
autologous bone marrow cells transplantation (BMCs-Tx)
in patients with chronic myocardial infarction beneficially
affects postinfarction remodelling. In this randomized
controlled study we analyzed the influence of intracoronary
autologous freshly isolated bone marrow cells transplanta-
tion by use of point of care system on cardiac function and
on the functional activity of bone marrow derived circulat-
ing progenitor cells (BM-CPCs) in patients with ischemic
heart disease (IHD).
Methods 56 patients with IHD were randomized to either
received freshly isolated BMC-Tx or a control group that
did not receive cell therapy. The functional activity of
BM-CPCs in peripheral blood (PB) was measured by
migration assay and colony forming unit assay pre- and 3,
6 as well as 12 months after procedure. Global ejection
fraction (EF) and infarct size area were determined by left
ventriculography.
Results Intracoronary transplantation of autologous freshly
isolated BMCs led to a significant reduction of infarct size
and an increase of global EF as well as infarct wall
movement velocity after 3 and 12 months follow-up
compared to control group. The colony-forming capacity
of BM-CPCs significantly increased 3, 6 and 12 months
after cell therapy compared to pre BMCs-Tx and control
group (CFU-E: p<0.001, CFU-GM: p<0.001). Likewise,
we found significant increase of migratory response to
stromal cell-derived factor 1 (SDF-1) and vascular endo-
thelial growth factor (VEGF) after cell therapy compared to
pre BMCs-Tx (SDF-1: p<0.001, VEGF: p<0.001) and to
control (SDF-1: p<0.001, VEGF: p<0.001). There was no
significant difference of migratory- and colony forming
capacity between pre- and 3, 6, 12 months after coronary
angiography in control group without cell therapy.
Conclusions Intracoronary transplantation of autologous
freshly isolated BMCs by use of point of care system may
lead to improvement of BM-CPCs functional activity in
peripheral blood, which might increase the regenerative
potency in patients with IHD.
Keywords Migration capacity.Colony forming capacity.
Ischemic heart disease.Bone marrow cell transplantation
Introduction
Circulating progenitor cells (CPCs) are primitive bone
marrow cells (BMCs) that have the capacity to proliferate,
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DOI 10.1007/s12015-010-9220-8migrate, and differentiate into various mature cell types [1–
3]. Furthermore, these cells circulate in the peripheral blood
(PB), and implicate in neoangiogenesis after tissue ischemia
[4, 5]. Cell therapy is a promising novel option to improve
vascularization or cardiac regeneration [6]. In animal
models, bone marrow-derived stem/progenitor cell infusion
improves cardiac function and neovascularization after
myocardial infarction [7–10]. Additionally, clinical trials
indicate a benefical effect of intra coronary infusion of
BMCs or circulating progenitor cells (CPCs) on myocardial
function in patients with acute myocardial infarction (AMI)
[11–15]. Moreover, it has been suggested that cardiovascu-
lar risk factors (CVRFs) are associated with reduction of
functional activity of BM-CPCs in patients with coronary
artery disease as well as in healthy men [16, 17]. It is
unknown whether freshly isolated BMCs transplantation
and the functional activity of BM-CPCs in PB have
beneficially affects postinfarction remodelling. In this
prospective randomized control trial, we analyzed the
influence of intracoronary freshly isolated cell therapy by
use of point of care system on cardiac function and on the
functional activity of the bone marrow derived circulating
progenitor cells (BM-CPCs) in patients with ischemic heart
disease (IHD).
Methods
Patients
In a prospective randomized controlled trial, patients
between 18 and 80 years of age were eligible for inclusion
in this study if they had had a documented MI at least
3 months and had a clear-cut demarcated region of left
ventricular dysfunction with an open infarct-related coro-
nary artery at the time of stem cell therapy. Exclusion
criteria were the presence of acutely decompensated heart
failure with a New York Heart Association (NYHA) class
of IV, infectious or inflammatory disease, active bleeding,
s u r g e r yo rt r a u m aw i t h i n2m o n t h s ,r e n a lo rl i v e r
dysfunction, thrombocytopenia, or anemia, alcohol or drug
dependency, a history of other severe chronic diseases or
cancer, or unwillingness to participate. The local ethics
committee approved the study protocol. All IHD patients
were discharged with standard medication consisting of
acetylsalicylic acid and/or clopidogrel, an ACE inhibitor, a
ß-blocker and a statin.
Study Protocol
In this study 56 patients with IHD were randomly allocated
in a 2:1 ratio to either receive intracoronary autologous
freshly isolated BMCs-Tx, or a control group no stem cell
therapy. All patients suffered a transmural myocardial
infarction (MI) 28±14 months before stem cell therapy
(STX). All of these patients were treated acutely by PTCA
plus stent implantation. We performed in all patients of both
groups 8±2 months before cell transplantation a coronary
angiography as well as a left ventriculography and
presented with open infarct-related coronary arteries. These
patients were randomized to either receive intracoronary
autologous freshly isolated bone marrow cell (BMC)
transplantation, or to a control group without stem cell
therapy. Patients included in the stem cell group underwent
a bone marrow puncture and BM aspiration on day 1 after
admission. BMCs were separated. Subsequently, after
coronary angiography and left ventriculography, the BMCs
were freshly transplanted intracoronary. Patients in the
control group received only coronary angiography and left
ventriculography without any cell based therapy. In both
groups all patients with angiographically relevant coronary
restenosis (5 patients from the BMCs-Tx and 2 patients
from the control group) were treated by PTCA plus stent
implantation and have been excluded from the study. We
examined all patients in both groups after 3 and 12 months
by coronary angiography and left ventriculography. The
primary end point of the study was the change in global EF
as well as the size of infarcted area measured by left
ventriculography after 3, and 12 months. Secondary end
points were the functional activity of BM-CPCs immedi-
ately pre and 3, 6 as well as 12 months after procedure.
Functional status was assessed by NYHA classification and
brain natriuretic peptide (BNP: normal value <100 pg/ml)
level in PB in both groups (Fig. 1).
Figures 2 and 3
Preparation and Administrations of BMC
A total of approximately 120 mls of bone marrow was
aspirated from the iliac crest after local anesthesia and
mononuclear cells were isolated and identified including
CD34
+ and CD133
+. The bone marrow cell concentrate
suspension was isolated by use of point of care system
(Harvest BMAC System, Harvest Technologies GmbH,
Munich, Germany) according to the manufactures instruc-
tions for use to produce 20 mls of concentrated cells. The
concentrate consisted of a heterogeneous cell population
including hematopoietic, mesenchymal, other progenitor
cells as well as granulocytes and platelets.
After undergoing arterial puncture, all patients received
7500–10000 Units of heparin. Cell transplantation was
performed via the intracoronary administration route [12]
using four fractional infusions parallel to balloon inflation
over 2–4 min of 5 ml of cell suspension. All cells were
infused directly into the infarcted zone through the infarct
related artery via an angioplasty balloon catheter, which
Stem Cell Rev and Rep (2011) 7:646–656 647was inflated at a low pressure (4 atm) and was located
within the previously stented coronary segments. This
prevented back flow of cells and produced stop flow
beyond the site of balloon inflation to facilitate high-
pressure infiltration of cells into the infarcted zone with
prolonged contact time for cellular migration. Three months
after catheter-guided cell transplantation, all functional tests
were repeated, including coronary angiography and left
ventriculography. There were no procedural or cell-induced
complications and there were no side effects in any patients.
Coronary Angiography and Left Ventriculography
Patients in both groups underwent left heart catheterization,
left ventriculography and coronary angiography. Cardiac
function and infarct size were determined by left ventricu-
lography. Cardiac function was evaluated by global EF and
by auxotonic myocardial contractility index, evaluated by
the wall movement velocity of the infarcted area. Global EF
was measured with Quantcor software (Siemens, Erlangen/
Germany). To quantify the size of infarct area we used the
centreline method according to Sheehan [18] by plotting
five axes perpendicular to the long axis of the heart in the
main akinetic or dyskinetic segment of ventricular wall.
Systolic and diastolic lengths were then measured by two
independent observers, and the mean difference was
divided by systolic duration in seconds. The follow-up
was 3 and 12 months after the treatment. All hemodynamic
investigations were obtained by two independent observers.
Isolation and Cultivation of BM-CPCs
20 ml peripheral venous blood was taken using a BD
Vacutainer CPT™ from each patient. BM-CPCs were
Fig. 1 Enrollment and follow-
up analysis of trial
648 Stem Cell Rev and Rep (2011) 7:646–656isolated by density gradient centrifugation. After 2 washing
steps, cells were resuspended in 1 ml EBM2-medium (Cell
system). The number of isolated BM-CPCs were deter-
mined in a Neubauer chamber [17, 19].
Assessment of Migration Assay
A total of 1×10
6 BM-CPCs were resuspended in 250 μlX -
Vivo and placed in the top compartment of a Boyden
Chamber. This chamber was placed in a 24-well culture
dish contained either only EBM-2 medium or 100 ng/ml
stromal cell derived factor-1 (SDF-1) or 100 ng/ml vascular
endothelial growth factor (VEGF) in EBM2-medium. After
24 h of incubation at 37°C transmigrated cells were counted
by 2 independent investigators [17, 19]. Quantitative
evaluation of migrated cells to SDF-1 and VEGF were
analyzed in comparison to cells without chemokine in
blood samples of both groups. Values are expressed as% of
migrated cells without chemokine.
Assessment of Colony Forming Unit Assay
1×10
5 in BM-CPCs per ml were seeded in Methocult GF
H4435 (Stemcell Technologies). Culture dishes were
seeded with 1 ml cell suspension and then incubated at
37°C. Colony-forming unit erythroid (CFU-E) and CFU-
granulocyte/macrophage (CFU-GM) were studied under
phase-contrast microscopy and were counted after 14 days
of incubation by 2 independent investigators [19].
Safety Parameters
To assess any inflammatory response and myocardial
reaction after cell therapy, white blood cell count, the
serum levels of C-reactive protein (CRP) and of creatine
kinase (CK) were determined immediately before and after
treatment. Additional analysis was done directly after
transplantation and 3, 6, 12 months later: BNP level in
Fig. 3 a and b. Colony forming unit is expressed as number of
colonies per 1×10
5 seeded BM-CPCs. Values are mean ± SEM.
Colony forming capacity of BM-CPCs increased significantly 3, 6 and
12 months after cell therapy as compared to baseline and to control
group. No significant difference was observed in the colony forming
capacity between baseline and 3, 6, 12 months after coronary
angiography in patients without cell therapy. Bone marrow derived
circulating progenitor cell (BM-CPCs)
Fig. 2 a and b. Quantitative evaluation of migration capacity of BM-
CPCs. There was a significant increase of migratory response to SDF-
1 and VEGF 3, 6 and 12 months after intracoronary freshly isolated
BMCs-Tx compared to baseline and to control group, whereas there
was no significant difference between immediately pre and 3, 6,
12 months after coronary angiography in the control group. Bone
marrow cell transplantation (BMCs-Tx), stromal cell-derived factor 1
(SDF-1) and vascular endothelial growth factor (VEGF)
Stem Cell Rev and Rep (2011) 7:646–656 649PB, ECG at rest, 24-h Holter ECG and echocardiography.
Procedural complications were defined as any ventricular
arrhythmia, visible thrombus formation, distal emboliza-
tion, or injury of the coronary artery associated with the cell
infusion catheterization procedure.
Statistical Analysis
Quantitative data are presented with mean ± SD and
qualitative data are tabulated using absolute frequencies
and/or percentages. Differences between therapy groups for
qualitative variables were tested using Fisher’s-Exact-Test
due to small number of patients in therapy groups. Within
differences of quantitative variables in each therapy group
are compared using the Wilcoxon-Test for depending
samples, and differences between therapy groups of
quantitative variables are compared with the Wilcoxon-
Test for independent samples. Both of those nonparametric
Wilcoxon-Tests are preferred due to the more likely
expected non-normal distribution of the data. For all
statistical tests, a result will be seen as statistically
significant, if the corresponding two-sided p-value is
smaller or equal to 0.05. If the mean and the median did
not differ markedly for a variable, the graphical presenta-
tion of the data was be done using the mean and SD of this
variable. Statistical analysis was performed with SPSS for
Windows (Version 15.0)
Results
Baseline Characteristics of The Patients
We randomized 56 patients with IHD (2:1) in the study. 38
patients in the intervention group received freshly isolated
BMCs-Tx, whereas 18 patients in second group received no
intra coronary BMCs-Tx and served as a control. There
were no significant difference between the baseline charac-
teristics and demographics of patients between both groups
(Table 1).
Effect of BMCs Transplantation
Left Ventricular Function, Infarct Size and Infarct Wall
Movement Velocity
Global EF, LVEDV, LVESV, SVI, infarct size and the wall
movement velocity were measured by left ventriculography
in the first group immediately before and 3, 12 months after
BMCs-Tx as well as in the second group without BMCs-Tx
pre- and 3, 12 months after cardiac catheterization. There
were no significant baseline differences in global EF, infarct
size and infarct wall movement velocity between the two
groups (Tables 2 and 3 and Fig. 4a, b and c). 3 and
12 months after cell therapy, we observed a significant
increase of global EF and infarct wall movement velocity
compared to baseline. Furthermore, we found significant
decrease of infarct size after 3 and 12 months compared to
baseline (Table 2). Moreover, global EF and wall move-
ment velocity of the infracted area significantly increased 3
and 12 months after cell therapy compared to control group.
Infarct size significantly decreased 3 and 12 months after
BMCs-Tx as compared to control group without cell
therapy (Fig. 4a, b and c). Moreover, we found a significant
increase of SVI and decrease of LVESV whereas no
significant change was observed in LVEDV 3 and
12 months after cell therapy (Table 2). In the control group
there were no significant changes in global EF, LVEDV,
LVESV, SVI, infarct size and the wall movement velocity
of the infarcted area 3 and 12 months after coronary
angiography (Table 3).
Functional Status and Clinical Safety Parameters
To determine the functional status we assessed NYHA
classification in both groups by two independent and
blinded physicians. There were no significant differences
of at baseline NYHA classification and BNP levels between
both groups. We observed significant a improvement in
NYHA classification 3, 6 and 12 months after intracoronary
cell therapy, whereas there was no significant difference in
control group 3, 6 and 12 months after coronary angiog-
raphy. Furthermore, we found a significant decrease of
BNP level in PB three months after BMCs-Tx with no
significant difference observed in control group 3, 6 and
12 months after coronary angiography (Tables 2 and 3).
NYHA classification and BNP levels significantly de-
creased 3, 6 and 12 months after cell therapy compared to
control group (Fig. 5a and b).
ECG at rest, on exercise and 24-h Holter ECG revealed
no rhythm disturbances. There was no inflammatory
response or myocardial infarction (white blood cell count,
CRP, CK) after cell therapy. No immediate periprocedure as
well as post procedure adverse complications and no new
electrocardiographic changes or significant elevations in
CK or troponin as well as no inflammatory response were
observed in patients with BMC-Tx
Functional Activity of BM-CPCs After Cell Therapy
The functional capacities of BM-CPCs were measured by
migratory- and colony forming activity in both groups
immediately pre- and 3, 6, 12 months after index procedure.
The migratory response to SDF-1 and VEGF increased
significantly 3, 6 and 12 months after intra coronary BMCs-
Tx compared to baseline and to control group. In contrast,
650 Stem Cell Rev and Rep (2011) 7:646–656Table 1 Baseline clinical characteristics of patients with ischemic heart disease with bone marrow cells transplantation and control group without
transplantation
IHD with BMCs-Tx (n=38) IHD without BMCs-Tx (n=18) P
Age 62±10 60±9 NS
m/f 20/18 10/8 NS
Cardiovascular Risk Factors (%)
Hypertension 60 65 NS
Hyperlipidemia 60 65 NS
Smoking 80 80 NS
Diabetes 20 25 NS
Positive family history of CAD 20 10 NS
Transmural myocardial infarction, months before Tx 28±13 27±14 NS
No. of diseased vessels 1.9±0.5 2.0±0.6 NS
Infarct-related vessel (LAD/LCX/RCA) 22/8/8 10/5/3 NS
PTCA/Stent at the time of AMI 38/38 18/18 NS
Medication (%)
Aspirin 100 100 NS
Clopidogrel 100 100 NS
ACE inhibitor or AT II blocker 100 100 NS
Beta-blocker 100 100 NS
Aldosterone Antagonist 20 20 NS
Statin 100 100 NS
Laboratory parameters
CK U/L 2018±560 2000±740 NS
IHD Ischemic heart disease, BMCs-Tx Bone marrow cells transplantation, CAD Coronary artery disease, PTCA Percutaneous transluminal
coronary angioplasty, CK Creatine kinase, LAD Left anterior descending coronary artery, LCX Left circumflex artery, RCA Right coronary artery,
NS None significant. Quantitative data are presented with mean ± SD
Table 2 Cardiac function, clinical function status parameters and functional activity of BM-CPCs at baseline and 3, 6 as well as 12 months after
freshly isolated BMCs-Tx in the firstgroup
Immediately pre
BMCs-Tx
3 months after
BMCs-Tx
6 months after
BMCs-Tx
12 months after
BMCs-Tx
Global EF (%) 46±10 53±8 * 52±8 *
The size of infarct area (%) 27±9 19±8 ** 18 ±5 **
Infarct wall movement velocity (cm/s) 1.80±0.74 2.98±0.89 ** 3.45±0.5 **
LVEDV (ml) 138±34 139±32 *** 138±32 ***
LVESV (ml) 75±20 65±10 * 66±10 *
SVI (ml/m
2) 34±10 42±9 * 41±8 *
Migration capacity
Cytokine SDF-1 (%) 85±10 127±13 ** 130±20 ** 129±19 **
Cytokine VEGF (%) 92±9 134±15 ** 141±22 ** 142±28 **
Colony forming unit capacity (CFU)
Erythroid (CFU-E) 48±5 99±15** 116±22** 112±20**
Granulocyte Makrophage (CFU-GM) 13±3 32±5 ** 38±8 ** 40±7 **
BNP (pg/ml) 159±73 65±25 ** 65±27 ** 66±19 **
NYHA classification 2.4±0.4 1.69±0.6 ** 1.6±0.5 ** 1.6±0.6 **
Values are mean ± SD. BM-CPCs, Bone marrow derived circulating progenitor cells, NYHA New York Heart Association, BNP B-type natriuretic
peptide, Global EF Global ejection fraction, LVEDV End-diastolic volume, LVESV End-systolic volume, SVI Stroke volume index. There was no
significant difference in baseline cardiac function, clinical function status parameters as well as functional activity of BM-CPCs between both
groups at baseline. *p=0.01–0.001 (compared to baseline); **p<0.001 (compared to baseline); *** p=non significant (NS)
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12 months after coronary angiography in control group
(Fig. 2a and b, Tables 2 and 3). Likewise, there was a
significant increase of colony forming capacity 3, 6,
12 months after cell therapy as compared to baseline and
to control group. Interestingly, no significant difference was
observed in the colony forming capacity between baseline
and 3, 6, 12 months after coronary angiography in patients
without cell therapy (Fig. 3a and b, Table 2 and 3).
Discussion
In this prospective randomized controlled study we could
demonstrate improved functional activity of the bone
marrow derived circulating progenitor cells after intra
coronary autologous freshly isolated bone marrow cells
transplantation in patients with IHD.
Despite improved pharmacological therapy, congestive
heart failure remains the leading cause of cardiovascular
mortality in industrialized world [20]. The use of stem cell-
based therapy is becoming increasingly recognized as
having the potential to salvage damaged myocardium and
to promote endogenous repair of cardiac tissue, thus having
the potential for the treatment of heart failure [21, 22].
Experimental studies demonstrated that intravascular or
intramyocardial administration of BMCs or CPCs may
contribute to functional regeneration of infarcted myocar-
dium and enhance neovascularization of ischaemic myo-
cardium [7–10]. Clinical pilot and randomized trials
suggested, that the intracoronary infusion of autologous
BMCs is safe and feasible as well as beneficially affects left
ventricular contractile recovery and infarct size in patients
with AMI [11–15]. Moreover, BMCs have been injected
directly into the myocardium in patients with ischemic heart
disease and have been shown to have a benefical effect on
cardiac function [23–25]. Likewise, it was reported, that
intracoronary infusion of BMCs in patients with ischemic
heart disease improves left ventricular function [26, 27]. In
our study, we demonstrated that the infarct size reduced,
whereas the global EF and regional infarct wall movement
velocity increased 3 and 12 months after intracoronary cell
therapy in patients with IHD. This observation is in line
with the data of Strauer et al. [26]. and Assmus et al. [27].
In addition, we observed improvement in NYHA classifi-
cation as well as significant decrease of BNP level 3, 6 and
12 months after cell therapy. Cell isolation procedures are
crucial for the functional activity of the administered
cellular product. In our trial we chose to use a point of
care system for the preparation of the treating cell
composition. We demonstrated the same results for the first
time with intracoronary freshly isolated BMCs-Tx by use a
point of care system with Harvest BMAC-system for the
preparation of the treating cell composition, not Ficoll
gradient separation as in other studies. Unlike many
previously conducted trials that employed Ficoll gradient
separation as the method of cell collection, which produces
a very limited cell linage spectrum. The cellular composi-
Table 3 Cardiac function, clinical function status parameters and functional activity of BM-CPCs at baseline and 3, 6 as well as 12 months after
coronary angiography in control group without BMCs-Tx
Immediately pre coronary
angiography
3 months after coronary
angiography
6 months after coronary
angiography
12 months after coronary
angiography
Global EF (%) 46±10 47±7*** 46±9***
The size of infarct area (%) 29±9 28±9*** 26±8***
Infarct wall movement velocity (cm/s) 1.86±0.96 1.93±0.76*** 1.99±0.9***
LVEDV (ml) 141±28 142±31*** 140±30***
LVESV (ml) 76±17 75±15*** 76±16***
SVI (ml/m
2) 36±10 35±8*** 34±9***
Migration capacity
Cytokine SDF-1 (%) 88±10 91±10*** 90±10*** 85±16***
Cytokine VEGF (%) 98±5 102±9*** 100±20*** 98±15***
Colony forming unit capacity (CFU)
Erythroid (CFU-E) 51±5 49±10*** 49±13*** 50±15***
Granulocyte Makrophage (CFU-GM) 12±2 12±4*** 15±8*** 11±6***
BNP (pg/ml) 157±84 130±80*** 128±60*** 141±42***
NYHA classification 2.5±0.9 2.45±0.9*** 2.1±0.7*** 2.3±0.6***
Values are mean ± SD. BM-CPCs, Bone marrow derived circulating progenitor cells, NYHA New York Heart Association, BNP B-type natriuretic
peptide, Global EF Global ejection fraction, LVEDV End-diastolic volume, LVESV End-systolic volume, SVI Stroke volume index. There was no
significant difference in baseline cardiac function, clinical function status parameters as well as functional activity of BM-CPCs between both
groups at baseline. *p=0.01–0.001 (compared to baseline); **p<0.001 (compared to baseline); *** p=non significant (NS)
652 Stem Cell Rev and Rep (2011) 7:646–656tion of the concentrate, which was prepared by use a point
of care system, differs from that prepared using the Ficoll
method. The Ficoll composition contains predominantly
mononuclear cells (lymphocytes, erythroblasts and mono-
cytes) and very few granulocytes. The point of care system
concentrates contain nucleated cell population with mono-
nuclear cells and specific stem cell population (CD34+ and
CD133+) as well as the platelets from the marrow aspirate
(Table 4). Importantly, however, the point of care device
provided advantage of significantly higher yield of isolated
bone marrow cells compared to the Ficoll protocol. Thus, if
the number of infused cells in invivo neovascularization
model was adjusted for this higher yield of bone marrow
cells, the treatment effect was significantly greater com-
pared to Ficoll BMCs, as assessed by limb perfusion
mesearument [28]. One obvious difference in the two
compositions is the presence of significant numbers of
granulocytes and platelets in the point of care system
composition. Platelets and granulocytes have been shown
to have a positive effect on the neovascular potential of the
resulting concentrate. The presence of platelets within
composition could be important because it has been shown
that these platelet-derived mediators also potently enhance
postnatal angiogenesis. Iba and colleagues demonstrated
that implantation of mononuclear cells together with
Fig. 5 a and b. NYHA classification and BNP levels in both groups.
There were no significant differences of baseline NYHA classification
and of BNP level between two groups. 3, 6 and 12 months after cell
therapy there were a significant decrease of NYHA classification and of
BNP level compared to control group without cell therapy. Moreover, no
significant changes were observed in the control group at follow up
Fig. 4 a, b and c. Global EF, infarct size and the wall movement
velocity of the infarcted area were measured by left ventriculography
immediately pre and 3, 12 months after procedure in both groups. There
were no significant baseline differences in global EF, infarct size and in
infarct wall movement velocity between the two groups. Global EF and
infarct wall movement velocity significantly increased 3 and 12 months
after cell therapy as compared to control group. Furthermore, there was a
significant decrease of infarct size 3 and 12 months after cell
transplantationcomparedtocontrolgroupwithoutcelltherapy.Moreover,
no significant changes were observed in the control group at follow-up
Stem Cell Rev and Rep (2011) 7:646–656 653platelets into ischemic limbs more effectively augments
collateral vessel formation by supplying various angiogenic
factors, in which VEGF played a key role [29] Indeed,
Massberg and colleagues provided compel ling evidence
that platelets generate the critical signal that recruits CD34+
bone marrow cells and c-Kit+ Sca-1+ Lin- bone marrow-
derived progenitor cells to sites of injury [30]. Therefore,
these findings strongly support the notion that implanted
platelets play a pivotal role in stem and progenitor
recruitment and provide a rationale for the fact that point
of care system produced functional in vivo results similar to
or better than Ficoll. In our study despite higher number of
platelets we observed no immediate periprocedure as well
as post procedure adverse complications. In addition, unlike
Ficoll isolation where cells are resuspended in a serum free
medium, point of care system is always resuspended in the
patient’s own plasma. Thus, the isolated cells are not
removed from their natural plasma microenvironment,
which may be help to sustain the functionality of the cells.
This has been further supported by experimental study of
Hermann et al., who showed that the point of care system
composition to be significantly more bioactive than the
Ficoll composition. Intriguingly, however, due to the
greater yield of cells generated by use a point of care
system, the cellular product isolated from a given bone
marrow aspirate by use a point of care device may actually
translate into even greater therapeutic effects. Additionally,
practical aspects may also deserve consideration. Impor-
tantly, a major limitation of the Ficoll isolation procedure
for clinical applications is that it is strongly investigator
dependant, immensely time consuming and requires a good
manufacturing practice (GMP) facility. In this study we
were able to demonstrate that such complex methods are
not necessary to achieve established results. As the
concentration process by use of point of care system,
everything can be accomplished in one session without
adding excessive time to the overall procedure circum-
venting the previously mentioned disadvantages of the
Ficoll isolation process. The point of care device provides a
much shorter turnaround time. Therefore, this device
represents a cost-effective and time-efficient stand-alone
technique for the isolation of autologous bone marrow cells
suitable for cell therapy regimens in the rapidly growing
field of regenerative medicine.
Several hypotheses have been proposed about, how
intracoronary cell therapy improves myocardial function. I)
Experimental studies addressing the capacity of trans-
planted bone marrow-derived stem cells to differentiate
into the cardiomyogenic lineage yielded conflicting results.
Recent well-conducted studies suggest that the BMCs do
not transdifferentiate into cardiomyocytes but adopt mature
hematopoietic characteristics. In contrast to embryonic stem
cells, most adult stem or progenitor cells do not spontane-
ously differentiate into cardiomyocytes but rather require an
adequate stimulus to do so. II) Another proposed mecha-
nism is that cell therapy may increase angiogenesis and
improve blood supply to ischemic regions, potentially
aiding in the revascularization of hibernating myocardium
and inhibiting cardiomyocyte apoptosis. Additionally or
alternatively, the local microenvironment plays an impor-
tant role to induce cell fate changes by physical cell-to-cell
interaction or by providing paracrine factors promoting
tissue repair [31, 32].
Cell-based therapy is a promising option for treatment of
ischemic disease. However, cell therapy is in its early
stages, and various questions remain. BMCs are best
characterized and have been used in the majority of clinical
trials performed to date. BMCs contains a complex
assortment of progenitor cells, including hematopoietic
stem cells (HSCs), mesenchymal stem cells (MSCs) or
stromal cells and multipotential adult progenitor cells
(MAPCs) [33]. BM-CPCs is another population of progen-
itor cells that has also been shown to have therapeutic
potential in the pool of progenitor cells circulating within
the blood. BM-CPCs are capable of proliferating and
differentiating into endothelial cells and are therefore
candidates for vascular regeneration [34–36]. Experimental
and clinical studies suggest that the systemic application or
mobilization of stem cells and progenitor cells beneficially
influences the repair of endothelial cells after injury and the
progression of atherosclerosis [37–41]. Previous studies
demonstrate that risk factors for coronary artery disease
correlate with number and functional activity of BM-CPCs
[17]. Not only is the quantity of BM-CPCs altered, but their
Table 4 The cellular composition of bone marrow aspirate and bone marrow concentrate by use of point of care system in the group with BMCs-
Tx
Bone Marrow Aspirate (Pre Separation, 120 cc) Bone Marrow Concentrate (Post Separation, 20 cc)
Total nucleated cells (×10
6 ml) 25±9 99±25
CD34
+ cells (×10
6 ml) 0.21±0.07 0.95±0.1
CD133
+ cells (×10
6 ml) 0.07±0.004 0.35±0.02
Platelet count (×10
3/μl) 155±19 705±174
Viability of cells (%) 98±1.5
654 Stem Cell Rev and Rep (2011) 7:646–656function is also modified by ischemic conditions and
therapeutic interventions [19]. Migration is essential for
the stem/progenitor cells to invade the ischemic tissue.
SDF-1 and VEGF are both profoundly upregulated in
hypoxic tissue [42, 43] and thus represent physiologically
relevant chemoattractants for the recruitment of circulating
progenitor cells to sites of ischemia. Indeed, intramuscular
injection of the chemoattractant chemokine SDF-1 has
recently been shown to increase the number of incorporated
BM-CPCs and to improve neovascularization in vivo [44].
Thus, the migratory response toward SDF-1 may indeed
play a crucial role for integration of BM-CPCs in ischemic
tissue. In addition, the accumulation of cardiovascular risk
factors or an increased overall risk is associated with
impaired colony forming activity of CPCs in healthy men
[16]. We found significant increase of migratory activity
and colony forming activity after cell therapy in contrast to
control group without cell therapy. The occurrence of a first
major cardiovascular event (acute myocardial infarction,
hospitalization, revascularization or death from cardiovas-
cular causes) was associated with reduced BM-CPCs levels
and functional activity in patients with coronary artery
disease [45]. Moreover, intra coronary administration of
BMCs is associated with a significant reduction of major
adverse cardiovascular events after AMI [46]. Previous
studies demonstrate that patients with heart failure (HF)
show endothelial dysfunction and in HF, nitric oxide
production is diminished, whereas rate of endothelial
apoptosis is increased [47, 48]. Moreover, the impaired
neovascularisation in mice lacking eNOS is related to defect
in progenitor cell mobilization from bone marrow [49].
Mechanistically, the improved perfusion capacity, which
was demonstrated in the pilot TOPECARE- and REPAIR-
AMI trial in patients after cell therapy, may increase
epicardial artery shear stress and stimulate the endothelium
to release NO, which may enhance the functional activity of
BM-CPCs and exerts antiatherosclerotic functions [50, 51].
Additionally, The presence of immature circulating cells in
the peripheral blood has been advocated as a marker of an
organism’s regenerative capacity [52].
The primary limitation of this study is the lack of placebo
arm and the measurement of cardiac imaging. Moreover, for
better understanding we added left ventricular volume data in
ourstudy,whichwasalsoinvestigatedinseveraltrials[11, 12,
15, 26, 27]. Therefore, a placebo-controlled study will be
needed to validate the hypothesis.
In the present study we could demonstrate that intra-
coronary transplantation of autologous freshly isolated BMCs
improved global EF and reduced infarct size significantly in
patients with IHD after 3 and 12 months. Moreover, we
observed a significant improvement of BM-CPCs functional
activity even 3, 6 and 12 months after cell transplantation.
This interesting observation could be implemented in future
large-scale randomized studies, where the BM-CPCs func-
tional activity after transplantation may serve as predictor for
identifyingIHDpatientswithgreaterbenefitaftercelltherapy.
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